What did @morethanmuscle.nicholas actually say?
The creator laid out a three-compound protocol: oral Anavar (oxandrolone) as a troche starting at 25mg daily, testosterone injected twice weekly at a self-reported preferred dose of 180mg/week, and HCG to preserve fertility. His framing was personal and cautious. He said "more does not always mean better" and positioned HCG as keeping "the lights on" at the factory while testosterone shuts down natural production. He also acknowledged individual sensitivity differences and said he planned to titrate the Anavar upward after a few weeks based on response. These are not the claims of someone selling a miracle. They are, mostly, the claims of someone who has read the literature and has personal experience with these compounds.
Does the science back this up?
On the core claims, mostly yes. Twice-weekly testosterone injections do reduce peak-to-trough hormone fluctuations compared to once-weekly dosing, and that is well-supported. HCG genuinely does stimulate Leydig cell function and preserve intratesticular testosterone during exogenous androgen use. The Anavar troche delivery claim is where things get shakier.
The claim that twice-weekly injections reduce fluctuations is backed by pharmacokinetic data. Testosterone cypionate and enanthate have half-lives of roughly 7-8 days, and splitting doses flattens the curve. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) showed that more frequent administration better mimics physiological testosterone patterns. On HCG, Liu et al. (2005, Journal of Clinical Endocrinology and Metabolism) demonstrated that low-dose HCG co-administered with testosterone maintained intratesticular testosterone and sperm production in men on exogenous androgens. The creator's "factory" analogy is simplified but functionally accurate.
What did they get wrong (or right)?
The troche delivery mechanism deserves scrutiny. The creator said oxandrolone "dissolves into the blood vessels in your mouth," implying meaningful buccal absorption. Oxandrolone is a 17-alpha alkylated oral steroid. Its standard route is gastrointestinal absorption. Buccal absorption of oxandrolone is not well-established in the literature the way it is for, say, testosterone buccal systems. Whether a troche formulation produces reliable bioavailability comparable to oral tablets is genuinely uncertain, and compounded troche formulations are not FDA-approved, which adds another layer of variability.
The fertility claim about HCG is mostly right but incomplete. HCG can maintain intratesticular testosterone and support spermatogenesis, but recovery after exogenous androgen use is not guaranteed and is influenced by duration of use, baseline fertility, and age. His phrase "everything should in theory start functioning as normal again" is doing a lot of work. Jarow et al. (1999, Journal of Urology) found that recovery timelines vary significantly. Calling it reliable without caveats is optimistic.
What he got right: individual dose sensitivity is real. The assumption that 200mg/week is a universal sweet spot is not evidence-based. Personalized titration based on symptom response and labs is how responsible TRT should work.
What should you actually know?
This video presents a polypharmacy stack, testosterone plus an anabolic steroid plus HCG, as though it is a routine TRT protocol. That framing deserves pushback. Standard TRT guidelines, including those from the American Urological Association and Endocrine Society, do not include oxandrolone. Adding Anavar to TRT moves this from hormone replacement into performance enhancement territory, regardless of how measured the tone is.
Oxandrolone carries real hepatotoxicity risk due to its 17-alpha alkylation, even at lower doses. Pavlatos et al. (2001, Annals of Pharmacotherapy) documented liver enzyme elevations with oxandrolone use. The fact that the creator is starting low does not eliminate that risk. Anyone considering this protocol should be under physician supervision with regular liver function panels and a full hormone panel, including LH, FSH, estradiol, hematocrit, and PSA where appropriate.
- HCG requires a prescription and is not a fertility guarantee during TRT.
- Compounded oxandrolone troches are not FDA-approved and potency can vary between compounding pharmacies.
- This stack is not standard TRT. It is an enhanced protocol that carries additional risks beyond testosterone alone.
- Self-directed dose adjustments without physician oversight and lab monitoring are not safe practice.